|
Title
|
|
|
|
Nivolumab in squamous cell carcinoma of the head and neck
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Introduction: The prognosis of recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC) after failure of first line chemotherapy is dismal. Until the publication of the results of CheckMate 141, not a single agent provided any survival benefit as a second line treatment for R/M HNSCC.Areas covered: A comprehensive review of the literature was conducted on the role of nivolumab in HNSCC.Expert commentary: Nivolumab is approved by the Food and Drug Administration for the treatment of patients based on the results of CheckMate 141 showing an overall survival benefit as compared to standard care (single agent docetaxel, methotrexate, or cetuximab). Of particular interest are immune-related adverse events which should be managed according to published guidelines. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Expert review of anticancer therapy. - London, 2001, currens
|
|
|
Publication
|
|
|
|
London
:
Future Drugs
,
2018
|
|
|
ISSN
|
|
|
|
1473-7140
[print]
1744-8328
[online]
|
|
|
DOI
|
|
|
|
10.1080/14737140.2018.1456337
|
|
|
Volume/pages
|
|
|
|
18
:5
(2018)
, p. 409-420
|
|
|
ISI
|
|
|
|
000429352500001
|
|
|
Pubmed ID
|
|
|
|
29560755
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|